{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:33:18Z","timestamp":1792737198448,"version":"4.5.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9,1]]},"DOI":"10.1097\/qai.0b013e3181e544e0","type":"journal-article","created":{"date-parts":[[2010,6,26]],"date-time":"2010-06-26T08:50:12Z","timestamp":1277542212000},"page":"95-101","source":"Crossref","is-referenced-by-count":29,"title":["HIV-1 Drug Resistance Mutations Are Present in Six Percent of Persons Initiating Antiretroviral Therapy in Lusaka, Zambia"],"prefix":"10.1097","volume":"55","author":[{"given":"Raph L","family":"Hamers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Siwale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole L","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moheb","family":"Labib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbert","family":"van Hasselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy S","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Schuurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie M J","family":"Wensing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Van Vugt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias F","family":"Rinke de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-13-20210131","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1473-3099(09)70136-7","article-title":"Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.","volume":"9","author":"Gupta","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"R3-13-20210131","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/jama.288.2.181","article-title":"Time trends in primary HIV-1 drug resistance among recently infected persons.","volume":"288","author":"Grant","year":"2002","journal-title":"JAMA"},{"key":"R4-13-20210131","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJMoa013552","article-title":"Antiretroviral-drug resistance among patients recently infected with HIV.","volume":"347","author":"Little","year":"2002","journal-title":"N Engl J Med"},{"key":"R5-13-20210131","first-page":"958","article-title":"Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J. Infect.","volume":"192","author":"Wensing","year":"2005","journal-title":"Dis"},{"key":"R6-13-20210131","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1086\/644505","article-title":"Transmission of drug-resistant HIV-1 is stabilizing in Europe.","volume":"200","author":"Vercauteren","year":"2009","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"R7-13-20210131","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/135965350801302S01","article-title":"Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia.","volume":"13","author":"Abegaz","year":"2008","journal-title":"Antivir Ther"},{"issue":"Suppl 2","key":"R8-13-20210131","first-page":"83","article-title":"Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi.","volume":"13","author":"Kamoto","year":"2008","journal-title":"Antivir Ther"},{"issue":"Suppl 2","key":"R9-13-20210131","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/135965350801302S12","article-title":"Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006.","volume":"13","author":"Maphalala","year":"2008","journal-title":"Antivir Ther"},{"key":"R10-13-20210131","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1089\/aid.2007.0317","article-title":"Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe, Uganda.","volume":"24","author":"Ndembi","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"Suppl 2","key":"R11-13-20210131","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/135965350801302S09","article-title":"Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004.","volume":"13","author":"Pillay","year":"2008","journal-title":"Antivir Ther"},{"issue":"Suppl 2","key":"R12-13-20210131","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/135965350801302S08","article-title":"Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania.","volume":"13","author":"Somi","year":"2008","journal-title":"Antivir Ther"},{"key":"R13-13-20210131","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.296.7.782","article-title":"Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.","volume":"296","author":"Stringer","year":"2006","journal-title":"JAMA"},{"issue":"3","key":"R17-13-20210131","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.","volume":"4","author":"Bennett","year":"2009","journal-title":"PLoS One"},{"key":"R18-13-20210131","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1093\/bioinformatics\/bti607","article-title":"An automated genotyping system for analysis of HIV-1 and other microbial sequences.","volume":"21","author":"de Oliveira","year":"2005","journal-title":"Bioinformatics"},{"key":"R19-13-20210131","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/088922203762688667","article-title":"Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1.","volume":"19","author":"Handema","year":"2003","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R20-13-20210131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002030-200501030-00001","article-title":"The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models.","volume":"19","author":"Blower","year":"2005","journal-title":"AIDS"},{"key":"R21-13-20210131","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1468-1293.2008.00562.x","article-title":"Antiretroviral drug resistance among antiretroviral-naive persons with recent HIV infection in Thailand.","volume":"9","author":"Apisarnthanarak","year":"2008","journal-title":"HIV Med"},{"key":"R22-13-20210131","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1097\/QAD.0b013e328313bf87","article-title":"Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa.","volume":"22","author":"Barth","year":"2008","journal-title":"AIDS"},{"key":"R23-13-20210131","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1128\/JVI.68.3.1660-1666.1994","article-title":"Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J.","volume":"68","author":"Richman","year":"1994","journal-title":"Virol"},{"key":"R24-13-20210131","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00001432-200102000-00005","article-title":"Implications of antiretroviral resistance on viral fitness. Curr.","volume":"14","author":"Nijhuis","year":"2001","journal-title":"Opin Infect Dis"},{"key":"R25-13-20210131","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/QAD.0b013e32832ac34e","article-title":"The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.","volume":"23","author":"Hosseinipour","year":"2009","journal-title":"AIDS"},{"key":"R26-13-20210131","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1086\/587109","article-title":"Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.","volume":"46","author":"Marconi","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R27-13-20210131","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/135965350901400414","article-title":"HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme.","volume":"14","author":"Orrell","year":"2009","journal-title":"Antivir Ther"},{"key":"R29-13-20210131","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/135965350400900312","article-title":"Infrequent transmission of HIV-1 drug-resistant variants.","volume":"9","author":"Yerly","year":"2004","journal-title":"Antivir Ther"},{"key":"R30-13-20210131","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1128\/JCM.43.3.1395-1400.2005","article-title":"Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.","volume":"43","author":"Weber","year":"2005","journal-title":"J Clin Microbiol"},{"key":"R31-13-20210131","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/AAC.46.11.3437-3446.2002","article-title":"Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.","volume":"46","author":"White","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"R32-13-20210131","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1371\/journal.pmed.0050158","article-title":"Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy.","volume":"5","author":"Johnson","year":"2008","journal-title":"PLoS Med"},{"key":"R33-13-20210131","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/088922202753472801","article-title":"Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program.","volume":"18","author":"Schuurman","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R34-13-20210131","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/QAI.0b013e3181900141","article-title":"Viral load and CD4+ T-cell dynamics in primary HIV-1 subtype C infection.","volume":"50","author":"Novitsky","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R35-13-20210131","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/jmv.20071","article-title":"Measurement of HIV RNA in patients infected by subtype C by assays optimized for subtype B results in an underestimation of the viral load.","volume":"73","author":"Gottesman","year":"2004","journal-title":"J Med Virol"},{"key":"R36-13-20210131","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1128\/JCM.02414-07","article-title":"Performance of three commercial viral load assays, Versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep\/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants.","volume":"46","author":"Holguin","year":"2008","journal-title":"J Clin Microbiol"},{"key":"R37-13-20210131","first-page":"257","article-title":"Comparison of the Generic HIV Viral Load assay with the Amplicor HIV-1 monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: the Kesho Bora preparatory study.","volume":"253-","author":"Rouet","year":"163","journal-title":"J Virol Methods"},{"issue":"Suppl 2","key":"R38-13-20210131","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1086\/340202","article-title":"Biology of anemia, differential diagnosis, and treatment options in human immunodeficiency virus infection.","volume":"185","author":"Claster","year":"2002","journal-title":"J Infect Dis"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-201009010-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T08:07:51Z","timestamp":1740211671000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201009010-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181e544e0","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9,1]]}}}